Nautilus Biotechnology (NASDAQ:NAUT) Releases Earnings Results, Beats Estimates By $0.02 EPS

Nautilus Biotechnology (NASDAQ:NAUT) announced its earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02, Yahoo Finance reports. During the same period in the previous year, the company posted ($0.13) earnings per share.

Nautilus Biotechnology Stock Down 7.4 %

Nautilus Biotechnology stock traded down $0.20 during trading on Thursday, hitting $2.51. The stock had a trading volume of 92,198 shares, compared to its average volume of 76,118. Nautilus Biotechnology has a 1 year low of $2.19 and a 1 year high of $4.00. The stock’s 50 day moving average is $2.55 and its two-hundred day moving average is $2.68. The stock has a market cap of $314.40 million, a price-to-earnings ratio of -4.56 and a beta of 1.20.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Guggenheim initiated coverage on Nautilus Biotechnology in a research note on Thursday, June 27th. They issued a “buy” rating and a $6.00 target price on the stock. Jefferies Financial Group initiated coverage on Nautilus Biotechnology in a research note on Monday, June 3rd. They issued a “hold” rating and a $3.00 price objective on the stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.